Acadia Pharma (ACAD) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-192.7M
Depreciation	583K
Stock-based compensation	39.85M
Non-cash charge resulting from lease termination
Other
Prepaid expenses, receivables and other current assets	-2.89M
Other assets	-646K
Accounts payable	994K
Accrued expenses	14.09M
Deferred revenue	1.88M
Other long-term liabilities	-55K
Net cash used in operating activities
Purchases of investment securities
Maturities of investment securities
Proceeds from sales of property and equipment
Net cash provided by (used in) investing activities
Proceeds from issuance of common stock	515.51M
Repayments of long-term debt
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash	-2K
Net increase (decrease) in cash and cash equivalents	51.54M
Beginning of period	102.14M
End of period	153.68M

Entities mentioned with ACAD

View All Entities